N/A N=21 Randomized Treatment

The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble

Scleral Buckling

Bottom Line

View on ClinicalTrials.gov: NCT01843920 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2017

Primary outcome: Primary: Complete Resolution of Intraocular Gas Bubble — 40.4; 37.8 Duration in days, gas bubble

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Timolol-dorzolamide (Glaucoma drops) (Drug); standard post-operative topical drops (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Jason Hsu, MD
Primary completion: Apr 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Complete Resolution of Intraocular Gas Bubble	40.4; 37.8	—
SECONDARY Number of Participants With Return of Intraocular Pressure to Normal Levels	1; 0; 7; 7; 1; 0	—

Summary

A controlled clinical study comparing the effect of topical aqueous suppressants on intraocular gas duration.

Eligibility Criteria

Inclusion Criteria

Ability to provide written informed consent and comply with study assessments for the full duration of the study.
Have undergone eye surgery including scleral buckling or pneumatic retinopexy for treatment of retinal detachment other condition at the discretion of the investigator.

Exclusion Criteria

Prior surgery to treat glaucoma.
Current use of glaucoma eye drops.
Absence of a lens in the eye or presence of a lens implant in front of the iris (colored part of your eye).
Allergy or contraindication to any of the glaucoma drops being used in this study (e.g., sulfa allergy, asthma, chronic obstructive pulmonary disease (bronchitis or emphysema), slow heart rate).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01843920). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.